Ironwood Pharmaceuticals Inc(IRWD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:01 PM ET (Korea 10/27 05:01)
Full metrics table
| Index | RUT | P/E | 4.56 | EPS (ttm) | 0.77 | Insider Own | 3.71% | Shs Outstand | 165.2M | Perf Week | -1.69% |
| Market Cap | 0.58B | Forward P/E | 2.66 | EPS next Y | 7.63% | Insider Trans | -2.38% | Shs Float | 159.1M | Perf Month | -15.25% |
| Enterprise Value | 0.90B | PEG | 0.02 | EPS next Q | 0.32 | Inst Own | 98.52% | Short Float | 9.79% | Perf Quarter | -7.89% |
| Income | 0.13B | P/S | 1.49 | EPS this Y | 715.56% | Inst Trans | 1.65% | Short Ratio | 7.81 | Perf Half Y | -13.37% |
| Sales | 0.39B | P/B | - | EPS next 5Y | 112.04% | ROA | 41.35% | Short Interest | 15.57M | Perf YTD | 3.86% |
| Book/sh | -0.98 | P/C | 7.31 | EPS past 3/5Y | -46.07% -25.92% | ROE | - | 52W High | -39.45% ($5.78) | Perf Year | 110.84% |
| Cash/sh | 0.48 | P/FCF | 3.12 | Sales past 3/5Y | -10.32% -5.33% | ROIC | 56.04% | 52W Low | 138.01% ($1.47) | Perf 3Y | -61.2% |
| Dividend Est. | - | EV/EBITDA | 3.77 | EPS Y/Y TTM | 1922.25% | Gross Margin | 99.53% | Volatility(W/M) | 4.25% 4.83% | Perf 5Y | -72.51% |
| Dividend TTM | - | EV/Sales | 2.3 | Sales Y/Y TTM | 26.19% | Oper. Margin | 60.64% | ATR (14) | 0.18 | Perf 10Y | -68.89% |
| Dividend Ex-Date | - | Quick Ratio | 6.06 | EPS Q/Q | 123.29% | Profit Margin | 33.36% | RSI (14) | 39.18 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.06 | Sales Q/Q | 32.62% | SMA20 | -5.07% ($3.69) | Beta | 0.25 | Target Price | $6.1 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -12.84% ($4.02) | Rel Volume | 0.57 | Prev Close | $3.46 |
| Employees | 100 | LT Debt/Eq | - | EPS/Sales Surpr. | -3.13% -1.57% | SMA200 | -12.56% ($4) | Avg Volume(3M) | 1.99M | Price | $3.5 |
| IPO | 2010/2/3 | Option/Short | Yes/Yes | Trades | 4488 | Volume | 1,131,287 | Change | 1.16% |
💊 Ironwood Pharmaceuticals is a U.S. specialty pharmaceutical company focused on treatments for gastrointestinal (digestive) disorders. Its key asset is LINZESS (generic name: linaclotide), a treatment for irritable bowel syndrome and chronic idiopathic constipation, and it operates a pipeline targeting unmet needs in the digestive disease space.
Over the past 1 year, roughly in the middle
39% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
IRWD makes money exceptionally well
Of every $100 in sales, $60.64 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +715.6% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $377. Peers typically go for $1,429. Compared with its own 3-year average, it is 53% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -72.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 98.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #36 of 83 in the industry
Based on market cap of $578M.
IRWD#36 Ironwood Pharmaceuticals Inc $578M PER 4.6 
EVO#37 Evotec SE ADR $540M PER - 
AQST#38 Aquestive Therapeutics Inc $498M PER - 
EOLS#39 Evolus Inc $474M PER - 
KMDA#40 Kamada Ltd $458M PER 20.8 
FAQ
What kind of company is IRWD?
IRWD belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of IRWD?
The market cap of IRWD is approximately $578M, ranking 3,007 within its sector.
What is the P/E ratio of IRWD?
IRWD has a P/E ratio of approximately 4.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IRWD?
IRWD has recorded a 52-week high of $5.78 and a low of $1.47.
